Archives
-
Galectin-1, FIP200, and Hepatic Steatosis
2026-10-05
A 2026 International Immunopharmacology study identifies a Galectin-1–FIP200 interaction as a previously unrecognized mechanism linking impaired autophagy with hepatic steatosis and insulin resistance. Its multimodal evidence supports a mechanistic model in which Galectin-1 disrupts ULK-complex function, while also underscoring the limits of overexpression models and the need for validation in human disease.
-
Bestatin Inhibition of Leucine Aminopeptidase
2026-10-05
The 1991 PNAS study used high-resolution X-ray crystallography to show how Bestatin binds bovine lens leucine aminopeptidase and coordinates a catalytic zinc ion. Its structural model connected inhibitor binding with a possible tetrahedral intermediate in peptide hydrolysis, while also clarifying which conclusions remain specific to this enzyme system.
-
(S)-(+)-Methoprene: Juvenile Hormone Signaling
2026-10-04
(S)-(+)-Methoprene is a juvenile hormone analog used to study Met-linked developmental signaling in arthropods. Evidence supports its value for interpreting insect metamorphosis inhibition and hormone-regulated development, but locust miRNA findings do not establish identical effects across species or tissues.
-
Flumequine: Evidence, Mechanism, and Research Context
2026-10-03
Flumequine is marketed as a DNA topoisomerase II inhibitor for mechanistic research, but the supplied evidence is limited. This overview separates vendor-reported properties from findings in Schwartz’s dissertation, examines conceptual applications in DNA replication and drug-response research, and defines key evidence and applicability limits.
-
Live-Dead Bacterial Staining Kit for Nanotherapy
2026-10-01
Use the Live-Dead Bacterial Staining Kit to pair membrane-integrity imaging with nanomaterial efficacy studies, including Fe3O4@ZIF-8 research. This practical workflow emphasizes controls, quantitative image analysis, and troubleshooting so fluorescence results can complement—but not replace—culture-based viability measurements.
-
ABT-737 and the Next Logic of Mitochondrial Apoptosis
2026-10-01
A mechanistic and translational guide to using ABT-737 as a BCL-2 protein inhibitor, connecting mitochondrial apoptosis biology with study design in lymphoma, multiple myeloma, small-cell lung cancer, and acute myeloid leukemia.
-
Omeprazole A2845: Gastric Acid Research Guide
2026-09-30
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled studies of gastric acid secretion, proton pump inhibition, and antiulcer activity. This guidance addresses stock preparation, assay controls, and handling limits; the material is for scientific research only and is not intended for diagnostic or medical use.
-
Sumatriptan: From Receptor Assay to Migraine Care
2026-09-30
Sumatriptan Succinate connects 5-HT1 receptor pharmacology with practical migraine research and pediatric emergency-care decisions. This guide translates receptor selectivity, inflammatory readouts, metabolism, and clinical pathway evidence into a mechanism-aware experimental framework.
-
ATS-9R Targeted Gene Silencing in Adipose Tissue
2026-09-29
ATS-9R, also called Adipocyte-targeting sequence-9-arginine, is a non-viral peptide carrier for targeted nucleic acid delivery to white adipose tissue. Its Prohibitin-mediated endocytosis mechanism supports gene silencing in adipocytes and adipose tissue macrophages in obesity and metabolic disease models.
-
V5 Tagging as a Translational Measurement Strategy
2026-09-29
The V5 Epitope Tag Peptide can be more than a reagent for confirming recombinant protein expression. Used as a defined antigenic control, it helps researchers separate construct biology from antibody performance, connect Western blot and immunoprecipitation workflows with advanced imaging, and build more decision-ready translational evidence.
-
Propranolol in Hypertension: Mechanism and Evidence
2026-09-28
The reference editorial positioned Propranolol as an important early beta-blocker for hypertension while emphasizing individualized dose titration, patient selection, and uncertainty about its precise antihypertensive mechanism. Its enduring value is methodological: it links β-adrenergic physiology, cardiovascular regulation, clinical response, and safety constraints without reducing treatment decisions to a fixed dose.
-
AmpliFold Capture-and-Release Boosts LFA Sensitivity
2026-09-28
The AmpliFold strategy separates analyte capture from final signal detection: complexes are collected over a broad membrane area, released by cleaving a disulfide linker, and rebound at a narrower detection region. In a HER2 model, this capture-and-release design improved sensitivity by up to 16-fold, including tests with large nanoparticles and spiked human serum, while retaining a multistep workflow reported to take under 30 minutes.
-
EPI-001: Reading AR-Linked Metastasis in TNBC
2026-09-27
EPI-001, an androgen receptor N-terminal domain inhibitor, offers a way to investigate AR-linked behavior beyond tumor-cell growth. This article examines what recent TNBC evidence supports, how to interpret its assays, and where the findings remain preliminary.
-
Calpain Inhibitor I, ALLN: Practical Workflow
2026-09-26
Calpain Inhibitor I, ALLN (A2602) is a cysteine-protease inhibitor for experiments examining calpain and selected cathepsin activity, including apoptosis assays and ischemia-reperfusion injury models. It is for research use only; aqueous preparation is unsuitable, and its activity against multiple proteases means results should not be interpreted as calpain-specific without orthogonal controls.
-
Single-Molecule Screening for Fast-Dissociating Antibodies
2026-09-25
Miyoshi and colleagues describe a semi-automated single-molecule TIRF assay that identifies specific, fast-dissociating antibodies directly from hybridoma cultures. The resulting Fab probes support multiplexable imaging and revealed rapid espin turnover within stereocilia actin cores, connecting antibody-screening kinetics to a biological process that conventional stable-binding probes may obscure.